Telephone: 1-850-444-9500 | Toll Free: 1-888-839-3775
Raptiva®
Raptiva®, a once-weekly injection which suppresses the immune system to reduce psoriasis flare-ups, has been removed from the market after it was linked to the risk of development of progressive multifocal leukoencephalopathy (PML), a fatal brain infection, according to the U.S. Food and Drug Administration.
Raptiva® is one of the drugs in a new class called monoclonal antibodies. Two other drugs in the class have also been associated with the risk of PML. Tysabri® was also removed from the market. Rituxan®, which is made by the same company as Raptiva®, Genentech, is still on the market but doctors have received warnings from the company to watch closely for signs or symptoms of PML in patients receiving Rituxan® injections.
Psoriasis is an autoimmune disease that usually shows up on the skin and can also manifest as psoriatic arthritis, according to the National Psoriasis Association.
PML is a rare, progressive, demyelinating disease of the central nervous system that usually leads to death or severe disability. It is characterized by progressive damage to the white matter of the brain. There are no known interventions that can reliably prevent or adequately treat PML. The signs of PML include confusion, dizziness or loss of balance, difficulty talking or walking, and vision problems.
If you or someone you love developed progressive multifocal leukoencephalopathy or suffered other adverse effects after using Raptiva®, you may be entitled to financial compensation. Please fill out our online form, or call 1-850-444-9500 or toll free at 1-888-839-3775 to discuss your valuable legal rights with one of the experienced defective drug attorneys at our firm.
Evers & Preston, PL
609 West Chase Street
Pensacola, FL 32502-4711
Telephone: 1-850-444-9500 | Toll Free: 1-888-839-3775
